Classification of idiopathic inflammatory myopathies

The Inflammatory Myopathies

Volumn , Issue , 2009, Pages 15-28

  Miller, Frederick W ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Clinicopathologic; Environmental; Genetic; Myositis specific autoantibodies; Phenotypes; Serologic

Indexed keywords

EID: 84892254924     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-827-0_2     Document Type: Chapter

References (63)

1. Baer AN. Differential diagnosis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2006;8:178-87.
2. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977;56:255-86.
3. Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52:2607-15.
4. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
5. van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, Dinant HJ, Linssen WH, Wokke JH, de Visser M. Polymyositis: an overdiagnosed entity. Neurology. 2003 Aug. 12;61(3):316-21.
6. Miller FW, Rider LG, Plotz PH, et al. Polymyositis: an overdiagnosed entity. Neurology 2004;63:402.
7. Miller FW. Inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. In: Koopman W, Moreland L, eds. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia: Lippincott, Williams and Wilkins, 2004:1593-620.
8. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006;54:597-613.
9. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
10. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84:231-49.
11. Rider LG, Miller FW. New perspectives on the idiopathic inflammatory myopathies of childhood. Curr Opin Rheumatol 1994;6:575-82.
12. Reed AM, Mason T. Recent advances in juvenile dermatomyositis. Curr Rheumatol Rep 2005;7:94-8.
13. Pachman LM. Juvenile dermatomyositis: immunogenetics, pathophysiology, and disease expression. Rheum Dis Clin North Am 2002;28:579-602, vii.
14. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992;326:363-7.
15. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.
16. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007;66:1345-9.
17. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418-24.
18. Engel AG, Franzini-Armstrong C. Myology. 3rd ed. New York: McGraw-Hill, 2004.
19. Yanmaz Alnigenis MN, Kolasinski SL, Kalovidouris AE. Focal myositis: a review of 100 previously published cases and a report of 2 new cases [letter]. Clin Exp Rheumatol 1999;17:631.
20. Noel E, Tebib J, Walch G, Vauzelle JL, Bouvier M. Focal myositis: a pseudotumoral form of polymyositis. Clin Rheumatol 1991;10:333-8.
21. Nuovo MA, Norman A, Chumas J, Ackerman LV. Myositis ossificans with atypical clinical, radiographic, or pathologic findings: a review of 23 cases. Skeletal Radiol 1992;21:87-101.
22. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet 1998;352:347-52.
23. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008;47:324-8.
24. Gunawardena H, Betteridge ZE, McHugh NJ. Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 2008;20:675-80.
25. Fritzler MJ, Wiik A, Tan EM, et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J Rheumatol 2003;30:2374-81.
26. Miller FW, Hess EV, Clauw DJ, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000;43:243-9.
27. Gourley M, Miller FW. Mechanisms of disease: environmental factors in the pathogenesis of rheumatic disease. Nat Clin Pract Rheumatol 2007;3:172-80.
28. Takahashi K, Ogita T, Okudaira H, Yoshinoya S, Yoshizawa H, Miyamoto T. D-Penicillamineinduced polymyositis in patients with rheumatoid arthritis. Arthritis Rheum 1986;29:560-4.
29. Miller FW. Genetics of environmentally-associated rheumatic disease. In: Kaufman LD, Varga J, eds. Rheumatic diseases and the environment. London: Arnold, 1999:33-45.
30. Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 2007;19:67-73.
31. Dourmishev AL, Dourmishev LA. Dermatomyositis and drugs. Adv Exp Med Biol 1999;455:187-91.
32. Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol 2006;62:473-9.
33. Bannwarth B. Drug-induced myopathies. Expert Opin Drug Saf 2002;1:65-70.
34. O'Hanlon T, Koneru B, Bayat E, et al. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. Arthritis Rheum 2004;50:3646-50.
35. Shamim EA, Rider LG, Miller FW. Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2000;12:482-91.
36. Rider LG, Gurley RC, Pandey JP, et al. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis Rheum 1998;41:710-9.
37. Rider LG, Shamim E, Okada S, et al. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum 1999;42:1285-90.
38. Shamim EA, Rider LG, Pandey JP, et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002;46:1885-93.
39. Arnett FC, Reveille JD, O'Hanlon T. HLA-DRB1 alleles in a Caucasian population from Houston, TX USA. Hum Immunol 2004;1238-41.
40. O'Hanlon TP, Carrick DM, Arnett FC, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. Medicine (Baltimore) 2005;84:338-49.
41. O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006;85:111-27.
42. O'Hanlon TP, Rider LG, Mamyrova G, et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 2006;54:3670-81.
43. Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2005;8:R13.
44. Needham M, Mastaglia FL, Garlepp MJ. Genetics of inclusion-body myositis. Muscle Nerve 2007;35:549-61.
45. Wedderburn LR, McHugh NJ, Chinoy H, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007;46:1786-91.
46. Mamyrova G, O'Hanlon TP, Monroe JB, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006;54:3979-87.
47. Chinoy H, Ollier WE, Cooper RG. Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies? Curr Opin Rheumatol 2004;16:707-13.
48. Chinoy H, Salway F, John S, et al. Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. Ann Rheum Dis 2007;66:970-3.
49. Chinoy H, Platt H, Lamb JA, et al. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients 1. Arthritis Rheum 2008;58:3247-54.
50. O'Hanlon TP, Rider LG, Schiffenbauer A, et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum 2008;58:3239-46.
51. Gregersen PK. Modern genetics, ancient defenses, and potential therapies. N Engl J Med 2007;356:1263-6.
52. Dugoujon JM, Guitard E, Senegas MT. Gm and Km allotypes in autoimmune diseases. G Ital Cardiol 1992;22:85-95.
53. Miller FW. Classification and prognosis of inflammatory muscle disease. Rheum Dis Clin North Am 1994;20:811-26.
54. Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-86.
55. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
56. Miller FW. Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies. JAMA 1993;270:1846-9.
57. Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep 2006;8:196-203.
58. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006;54:3682-9.
59. Love LA, Miller FW. Noninfectious environmental agents associated with myopathies. Curr Opin Rheumatol 1993;5:712-8.
60. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003;48:2285-93.
61. Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol 2008;59:872-80.
62. Gherardi RK, Authier FJ. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin North Am 2003;23:699-712.
63. Bassez G, Authier FJ, Lechapt-Zalcman E, et al. Inflammatory myopathy with abundant macrophages (IMAM): a condition sharing similarities with cytophagic histiocytic panniculitis and distinct from macrophagic myofasciitis. J Neuropathol Exp Neurol 2003;62:464-74.